• MJHLS Brand Logo

© 2021 MJH Life Sciences™ and Neurology Live. All rights reserved.

Peer Exchange

Strategies in Treating Relapsing-Remitting Multiple Sclerosis
EP. 1: Diagnosing MS: Referring to the Revised McDonald Criteria
EP. 2: Diagnosing MS: Criteria Used to Assess Lesions
EP. 3: Differentiating Between the Subtypes of MS
EP. 4: Early, Aggressive Therapy for Relapsing-Remitting MS
EP. 5: Treating RRMS: Low Vs High-Efficacy Therapy
EP. 6: Counseling Patients On High-Efficacy Therapy for RRMS
EP. 7: High-Efficacy Therapies Used to Treat RRMS
EP. 8: Impressions of a 35-Year-Old Man With Relapsing MS
The Changing Landscape in the Treatment of Spinal Muscular Atrophy
EP. 1: An Overview of the SMA Classification Criteria
EP. 2: The Importance of Newborn Screening for SMA
EP. 3: Signs of Symptoms of Spinal Muscular Atrophy
EP. 4: Genetic Testing and Diagnostic Delay in SMA
EP. 5: Impact of Genetic Testing on Treatment Considerations
EP. 6: The Role of Primary Care Physicians in Diagnosing SMA
EP. 7: The Evolving Therapeutic Landscape for SMA
EP. 8: The ENDEAR Trial of Nusinersen in Infantile-Onset SMA
Progress in the Treatment of Amyotrophic Lateral Sclerosis (ALS)
EP. 1: An Overview of Causes and Risk Factors for ALS
EP. 2: Diagnosing ALS: Signs and Symptoms
EP. 3: Diagnosing ALS: Common Mimics
EP. 4: Counseling Patients on ALS Progression and Prognosis
EP. 5: Diagnostic Criteria and Staging Systems in ALS
EP. 6: Genetic Testing for Patients with ALS
EP. 7: Diagnosis and Management of ALS During COVID-19
EP. 8: Multidisciplinary Approach to Palliative Care in ALS
EP. 9: Challenges of Respiratory Care in Patients with ALS
EP. 10: Building a Dialogue on Life Sustaining Care in ALS
Management of Progressive Multiple Sclerosis
EP. 1: Clinical Subtypes of MS
EP. 2: Diagnosing SPMS
EP. 3: Classification and Diagnosis of SPMS
EP. 4: Treating PPMS Versus SPMS
EP. 5: Siponimod for SPMS Treatment
EP. 6: MS Treatment: EXPAND Study Versus ASCEND Study
EP. 7: Progressive MS Treatment: Ocrelizumab
EP. 8: Patient Selection in MS Treatment
EP. 9: Nonactive MS: Treatment Therapies
EP. 10: Ibudilast for Progressive Treatment
EP. 11: Monitoring Response in Progressive MS
EP. 12: Age Considerations: Patients With Nonactive MS Progression
EP. 13: Shared Decision Making and Complimentary Therapies in Progressive MS
EP. 14: MS: Nutrition and Managing Cognitive Impairment
EP. 15: Exercise and MS Fatigue
EP. 16: Future of MS Management
EP. 17: Advice for Managing MS
Recent Advances in the Treatment of Hereditary ATTR Amyloidosis (hATTR)
EP. 1: Overview of hATTR Amyloidosis
EP. 2: Prevalence of hATTR Amyloidosis
EP. 3: Disparities in Prevalence of hATTR Amyloidosis
EP. 4: Signs and Symptoms of hATTR Amyloidosis
EP. 5: Diagnosing hATTR Amyloidosis
EP. 6: Diabetes and hATTR Amyloidosis Neuropathy
EP. 7: Diagnostic Strategies in hATTR Amyloidosis
EP. 8: Genetic Testing in hATTR Amyloidosis
EP. 9: Tissue Biopsies in hATTR Amyloidosis
EP. 10: Identification of the Amyloid Protein 
EP. 11: Recent Advances in hATTR Amyloidosis Treatment
EP. 12: Evaluating hATTR Amyloidosis Therapy
EP. 13: Benefits of TTR Gene Silencers
EP. 14: Evaluating the Potential of Vultrisiran
EP. 15: Future Treatment of hATTR Amyloidosis
Updates in the Management of Relapsing Multiple Sclerosis
EP. 1: 2017 Changes to the McDonald Criteria: Diagnosing Multiple Sclerosis
EP. 2: Use of MRI in Diagnosing Multiple Sclerosis
EP. 3: Misdiagnosis of Multiple Sclerosis
EP. 4: Cerebrospinal Fluid in Diagnosing Multiple Sclerosis
EP. 5: Challenges in Optimally Treating Multiple Sclerosis
EP. 6: QoL Issues in the Management of Multiple Sclerosis
EP. 7: Multiple Sclerosis Fatigue
EP. 8: TRIUMPHANT-MS Trial: Fatigue in MS
EP. 9: OPTIMUM Phase 3 Trial: Secondary End Point Effect on Fatigue
EP. 10: Strategies for Choosing Initial Therapy in MS
EP. 11: Anti-CD20 Monoclonal Antibodies for Treatment of RMS
EP. 12: Cladribine for Treatment of RMS
EP. 13: S1P Receptor Modulators for Treatment of RMS
EP. 14: Fumarates for Treatment of RMS